production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today reported financial results for the ...

The Company currently has 12 listed patents for IGALMI in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations ... sales activity reflects rising utilization. Cost of Goods Sold: ...

Supplements promising similar results to Ozempic have taken over social media, but the TGA and health experts have concerns.

Revenue: $7 million, an increase of 10.2% year-over-year. Therapeutic Device Revenue: $6.5 million, up 8.5% driven by PulseVet's 24.5% growth. Diagnostics Segment Revenue: Approximately $500,000, an ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsLarry Heaton – Chief Executive OfficerMike ...